Objectives-During inflammation, cell adhesion molecules are modulated or redistributed for leukocyte transmigration.
T he endothelial junctions play a fundamental role in endothelial integrity, vascular permeability, and cellular traffic. 1 At least 2 types of cell-to-cell junctional structures have been identified in the endothelium: adherens junctions (AJ) and tight junctions (TJ). 2 These junctions are tightly regulated structures composed of several adhesion molecules interacting with cytoskeletal proteins. 3 Among the adhesive molecules, endothelial VE-cadherin 4 is localized in AJ and junctional adhesion molecule (JAM) 5 in TJ, whereas other molecules such as PECAM-1/CD31 (platelet endothelial cell adhesion molecule-1) and CD99 are not restricted to 1 type of junctional structure. 6 The inflammatory response is characterized by leukocyte infiltration from the circulation toward the tissues, after a multistep process in which proinflammatory endothelial activation results in increased vascular permeability and then in leukocyte adhesion and transmigration. 7 Endothelial activation is mediated by several inflammatory cytokines. Among them, TNF␣ increases the expression of cell adhesion molecules like ICAM-1 or VCAM-1 and induces the redistribution of junctional adhesion molecules such as PECAM-1, JAM, VE-cadherin, and CD99 which, in turn, promote the transendothelial migration of leukocytes. 8 We have previously shown that CD146 (S-Endo1 Ag) is a component of the endothelial junction localized outside defined junctional structures. 9 CD146, also referred to as MUC18, is a member of the immunoglobulin superfamily (IgSF) constitutively expressed in all types of human endothelial cells. 10, 11 CD146 is involved in the control of cell cohesion, as evidenced by its regulated expression during monolayer establishment, its involvement in the control of paracellular permeability, and its colocalization with the actin cytoskeleton. 9 The interaction of CD146 with cytoskeletal proteins triggers signaling pathways toward the focal adhesion plaques. 12 More recently, a report on a new blocking mAb directed against CD146 showed the importance of this protein in angiogenesis and tumor growth. 13 In agreement with this observation, CD146 knock-down in zebrafish clearly reduced intersomital vascularization. 14 In addition to the membrane-anchored form of CD146, a soluble form of CD146 (sCD146) has been identified in the supernatant of cultured human endothelial cells and in the plasma of healthy subjects. 15, 16 The plasma concentration of sCD146 is modulated in inflammatory diseases associated with endothelial alterations. 17 Although previous data have established that CD146 is involved in the control of endothelial permeability, 9, 18 its putative role in leukocyte transmigration has never been studied. Therefore, the aim of the present study was (1) to investigate the effect of TNF␣ on the cellular expression of CD146 and the release of sCD146 in cultured endothelial cells (HUVEC) and (2) to determine the role of membrane and soluble CD146 in monocyte transmigration.
Methods

Cells
Endothelial cells (HUVECs) were obtained from human umbilical cord vein as previously described. 19 The cells were maintained, subcultured in complete EGM-2 medium (Cambrex, France), and used at passage 2 or 3. No significant difference in cell count viability, assessed by Trypan blue exclusion, was observed after 48 hours of TNF␣ stimulation at 100 ng/mL as compared to control cells without TNF␣ (92Ϯ3% versus 95.6Ϯ1.6% of viable cells in unstimulated condition, nϭ5).
The THP-1 cell line, a human acute monocytic leukemia cell line, was maintained in RPMI 1640 medium with 10% fetal bovine serum under standard cell culture conditions. Monocytes were isolated from venous whole blood of healthy volunteers by Ficoll gradient centrifugation, followed by an adhesion step on plastic dishes (for 1 hour in RPMI 1640 medium with 10% fetal bovine serum) before scraping, as previously described. 20 This procedure yielded cells composed of more than 90% monocytes. In addition, using flow cytometry analysis, we verified that monocytes were not activated, as attested by the lack of difference in HLA DR expression between monocytes obtained using Ficoll separation alone or Ficoll separation followed by adhesion (not shown). For additional methods, see the online supplemental data.
Results
TNF␣ Increases CD146 Expression and Shedding
The cell surface expression of CD146 in response to TNF␣ was examined in HUVECs by flow cytometry analysis and compared to expression of ICAM-1, a TNF␣-inducible molecule. Dose-dependence (5 to 100 ng/mL) and time-course analysis of TNF␣ effect over a period of 48 hours (1 to 48 hours) showed no significant effect at 5 ng/mL TNF␣ whatever the time of stimulation. In contrast, a significant increase in CD146 expression was observed at 20, 50, and 100 ng/mL TNF␣ after 48 hours of stimulation without significant differences between the 3 doses ( Figure 1A) . Together, these data demonstrated that a significant effect on CD146 cell surface expression was obtained from 20 ng/mL of TNF␣ for 48 hours. This condition was used in all subsequent experiments. CD146 membrane expression gradually increased from 300.10 3 to 600.10 3 sites per cell while ICAM-1 membrane expression dramatically increased and reached a plateau at 18 hours ( Figure 1A ). To further analyze these effects, we performed quantitative RT-PCR and Western blotting experiments in HUVECs treated or not with TNF␣. Time-course showed a significant increase in CD146 mRNA between 4 hours and 24 hours without further increase at 48 hours. At this time, TNF␣ also significantly increased CD146 protein, as shown by Western blotting ( Figure 1B) .
Flow cytometry analysis of CD146 without or with TNF␣ treatment, after saponin permeabilization, confirmed that total CD146 expression was increased after TNF␣ treatment ( Figure 1C ). In addition, in unstimulated HUVECs, a significant increase in CD146 was observed in saponin-treated compared to saponin-untreated HUVECs, suggesting the existence of a cytoplasmic pool of CD146. In TNF␣stimulated HUVECs, this increase was no longer observed, consistent with a loss of this pool and delocalization of the molecule ( Figure 1C ).
We investigated whether TNF␣ generated the release of a soluble form of CD146. The concentration of sCD146 in HUVEC supernatants significantly increased after TNF␣ stimulation ( Figure 1D ). Additional experiments using HUVECs grown on Transwell filters indicated that, under TNF stimulation, sCD146 was preferentially released at the apical side but, in unstimulated HUVECs, sCD146 was at the same concentration both in the apical and basal medium ( Figure 1E ). As extracellular shedding is a major mechanism for generation of the soluble form, we analyzed the effects of several protease inhibitors on both soluble and membrane CD146. No effect was observed in the presence of inhibitors of serine protease (PMSF and 3, 4 DCI), aspartic protease (pepstatine), and cystein protease (E64) (not shown). In contrast, addition of GM6001, a broad-spectrum metalloproteinase inhibitor, reduced sCD146 release ( Figure 1D ) and significantly increased CD146 membrane expression in TNFstimulated HUVECs ( Figure 1F ).
TNF␣ Redistributes CD146 Toward the Junction and the Apical Membrane
Because data presented above suggested that TNF␣ stimulation could trigger the redistribution of CD146, the localization of the molecule was examined by confocal and electron microscopy.
Permeabilized cells were analyzed from apical to basal side through serial optical sections (0.5 m) on confocal microscopy ( Figure 2A) . No labeling was observed with the irrelevant IgG1 (not shown). In unstimulated HUVECs, CD146 was expressed both at the endothelial intercellular junction and inside the cytoplasm whereas a faint part of the molecule was found at the apical side ( Figure 2A ; a to d). In TNF␣-treated HUVECs, CD146 was concentrated at the intercellular junction ( Figure 2A ; cЈ and dЈ) and at the apical side of the cells as fluorescent patches (Figure 2A ; aЈ and bЈ). To confirm that CD146 redistributes to the junction and to the apical membrane, double labeling experiments were performed using CD146 and junctional (CD31) or apically localized (CD54) proteins ( Figure 2B ). Orthogonal images were also analyzed ( Figure 2B ). Stainings in nonpermeabilized conditions also confirmed this redistribution (supplemental Figure I, available online at http://atvb.ahajournals. org). Together, these experiments showed that CD146 is redistributed toward the junction and the apical membrane in TNF␣-treated HUVECs with an increase in CD146 expression ( Figure 2B ). CD146 immunogold labeling was performed and analyzed by electronic microscopy in HUVECs cultured on filters to preserve cell polarity. The specificity of the immunogold labeling was verified by the negative labeling obtained with the irrelevant mAb (not shown). In resting HUVECs, CD146 was uniformly distributed within the cytoplasm ( Figure 2C ; a) whereas it was clearly observed at the apical side of the membrane as patches of gold particles in TNF␣-stimulated cells ( Figure 2C ; b and c). Quantification of immunogold patches (defined as n Ͼ10 gold particles) in the different cell compartments indicated that TNF␣ stimulation led to an increase in the number of patches at the apical side of the cells with a concomitant decrease in the number of intracellular patches ( Figure 2C; d) . Together, these results indicate that TNF␣ stimulation induces the redistribution of CD146, both at the cellular junction and at the apical membrane of HUVECs.
Junctional CD146 Plays a Role in Monocyte Transmigration
The redistribution of CD146 from intracellular stores to the junction under TNF␣ treatment led us to hypothesize that CD146 could be involved in monocyte transmigration. Anti-CD146 mAb did not modify the adhesion of the monocyte cell line THP-1 on TNF␣-stimulated HUVECs (data not shown). In contrast, anti-CD146 mAb significantly reduced the THP-1 transmigration induced by TNF␣ stimulation ( Figure 3A) . Similar results were obtained using anti-CD146 Fab'2 fragments but not irrelevant IgG1 of Fab'2 fragments. The experiments were reproduced on freshly isolated mono-cytes for a shorter cell transmigration time. In these conditions, we also observed the inhibitory effect of anti-CD146 mAb on monocyte transmigration ( Figure 3A) . As the majority of monocytes were bound to platelets, we tested the possibility that monocyte-bound platelets influenced the effects observed. To this end, we performed transmigration experiments after platelet addition on THP-1. No effect of platelet addition was evidenced (data not shown).
The role of CD146 in monocyte transmigration was further confirmed by using CD146 siRNA ( Figure 3B ). CD146 siRNA transfection resulted in about 85% to 90% reduction in CD146 expression as measured by quantitative flow cytometry and Western blot ( Figure 3B ). THP-1 transmigration was significantly decreased in the presence of CD146 siRNA in both unstimulated and TNF␣-treated cells ( Figure  3B ). The same results were obtained by transfecting HUVEC with another CD146 siRNA (supplemental Figure II) .
Because CD146 is known to regulate endothelial permeability, we investigated the relative contribution of CD146 to endothelial permeability and THP-1 transmigration, in comparison with the junctional molecules VE cadherin (CD144) and PECAM 1 (CD31) (supplemental Figure III) . In basal condition (supplemental Figure IIIA) , anti-CD144 mAb increased endothelial permeability without modification of THP-1 transmigration, whereas anti-CD146 mAb, as well as anti-CD31 mAb, increased endothelial permeability and decreased THP-1 transmigration. After TNF␣ stimulation (supplemental Figure IIIB) , maximal endothelial permeability was achieved without any further effect of the various antibodies. However, anti-CD146 and anti-CD31 mAb still decreased THP-1 transmigration in a way similar to that observed in basal condition whereas anti-CD144 mAb had no effect. 
Soluble CD146 Increases Monocyte Transmigration Through the Endothelial Junction
We investigated the effects of sCD146 on endothelial permeability and monocyte transmigration (Figure 4 ). After TNF␣ stimulation, endothelial permeability was significantly increased ( Figure 4A ). Treatment with sCD146 (from 0 to 100 ng/mL) did not further affect endothelial permeability. In contrast, sCD146 modulated monocyte transmigration, according to a bell-shaped relationship. Indeed, experiments performed with THP-1 ( Figure 4B ) or freshly isolated monocytes ( Figure 4C ) indicated that transmigration was increased by sCD146 (from 0 to 25 and from 0 to 50 ng/mL, respectively), followed by a progressive decline up to 400 ng/mL.
To confirm the contribution of sCD146 to THP-1 transmigration, we performed experiments in which TNF␣-induced endothelial sCD146 release was inhibited by GM6001 ( Figure  4D ). In this condition, THP-1 transmigration was significantly reduced. Conversely, THP-1 transmigration was partially restored when sCD146 was added to HUVECs treated with GM6001. Similarly, THP-1 transmigration decreased significantly when the culture medium of TNF␣-stimulated HUVECs was removed before cell transmigration to discard sCD146 ( Figure 4E ). In both experiments ( Figure 4D and 4E), sCD146 levels were undetectable after GM6001 treatment or removing the medium (data not shown). In addition, we compared the effect of sCD146 incubation with both THP1 and HUVECs (previous condition), or preincubation with THP1 alone, or with HUVECs alone on THP1 transmigration ( Figure 4F ). Whatever the condition, we found a significant increase in THP1 transmigration relative to TNF␣. However, the effect of sCD146 observed in previous experimental conditions was reproduced when sCD146 was preincubated with THP1, but not with HUVECs.
Soluble CD146 Binds Monocytes Through a yet Unknown Counter-Receptor
Because sCD146 preincubation with monocytes is required for increasing their transmigration, we analyzed the ability of sCD146 to bind both monocytes (supplemental Figure IVA) and THP1 (supplemental Figure IVB) . Soluble CD146 binding was demonstrated by fluorescence microscopy (A and B: left panels) and by flow cytometry (A and B: middle panels), whereas no binding was detectable with an Ig G1-FITC or an antiCD146-FITC mAb (data not shown). Flow cytometry analysis showed that the binding of sCD146-FITC on THP1 and monocytes was competed away with unlabeled CD146 (A and B: middle panels). In addition, sCD146 bound on both cell types in a dose-dependent and saturable-manner (A and B: right panels). As platelets bound freshly isolated monocytes, we verified that sCD146-FITC was unable to bind isolated platelets (data not shown).
Finally, we showed that THP-1 adhered to immobilized sCD146 (supplemental Figure IVC) . This binding was specifically inhibited when THP-1 were preincubated with sCD146. As expected, control experiments showed that THP-1 adhered to CD31 antibodies but not to CD146 antibodies. These data are consistent with heterophilic binding of CD146 with a yet unknown ligand.
The Combined Action of Membrane CD146 and sCD146 in Monocyte Transendothelial Migration Does Not Involve Homophilic Interaction
To further examine the mechanisms underlying sCD146 effect on transmigration, we analyzed the effect of sCD146 on THP-1 transmigration in HUVECs transfected with CD146 siRNA with or without TNF␣ stimulation (supplemental Figure VA) . In both conditions, CD146 siRNA prevented the sCD146-induced increase in THP-1 transmigration observed in cells transfected with control siRNA, indicating that the effect of sCD146 on monocyte transmigration is dependent on cell membrane CD146. To investigate whether membrane CD146 establishes heterophilic or homophilic interactions, we quantified by flow cytometry the binding of sCD146-FITC to HUVEC transfected or not with CD146 siRNA (supplemental Figure VB) . We observed that sCD146 bound to HUVECs and that this binding was specific since it was competed away with unlabeled CD146 (supplemental Figure VB, left panel) . In addition, sCD146 binding was comparable in the absence or presence of CD146 (supplemental Figure VB, medium panel) , suggesting that sCD146 binding on HUVECs was not homophilic. Consistent with this hypothesis, SPR experiments (supplemental Figure VC) showed no interaction between immobilized sCD146 and a CD146-Fc protein or between immobilized CD146-Fc protein and sCD146 whereas binding was observed with anti-CD146 antibodies. In addition, adhesion experiments using immobilized Fc-CD146 fusion protein did not evidence binding with sCD146 (supplemental Figure VI) . Together, these data suggest the interaction of CD146 is heterophilic.
Discussion
To date, studies on CD146 in endothelial cells have mainly focused on its function in cell-cell cohesion and permeability, 9, 18 but very little is known about its role in inflammation.
Here, we report that TNF␣ increases CD146 expression at both the cellular junction and apical membrane of HUVEC, through CD146 synthesis and intracellular store redistribution. In addition, a soluble form of the molecule was released from the cell membrane via metalloproteinase-dependent shedding. Both membrane and soluble forms of CD146 are involved in monocyte transmigration through the endothelial monolayer.
Leukocyte transmigration occurs as a multistep cascade involving molecular interactions between leukocytes and endothelial cells. Endothelial junctional molecules display a spatiotemporal regulation in response to inflammatory stimuli such as TNF␣. 7 Whereas VE-cadherin plays a key role as a gate keeper of leukocyte migration with loosening of adhesive contacts between molecules on apposed cells, JAM-A, PECAM-1, and CD99 concentrate at this junction to interact with transmigrating leukocytes. 21 Transmigration is a sequential mechanism involving JAM-A, then PECAM-1, and finally CD99. 7, 22 It has been proposed that JAM-A is redistributed to the luminal surface under inflammatory conditions. Thereafter, JAM-A directs the leukocyte movement by homophilic interaction with other JAM-A molecules expressed on leukocyte membrane and promotes leukocyte adhesion and extravasation through binding to leukocyte LFA-1. 23 JAM-C has also been reported to regulate unidirectional monocyte transendothelial migration in inflammation. 24 When monocytes transmigrate, PECAM-1 is concentrated at the endothelial cell junctions and interacts with PECAM-1 expressed on the monocyte, in a homophilic way. Similarly, CD99 concentrates at the intercellular borders and interacts with other CD99 expressed on the surface of transmigrating monocytes. DNAM-1 has also been reported to be involved in the initial steps of transmigration but, to date, its role in inflammation is not known. 25, 26 CD146 is upregulated and redistributed by the proinflammatory cytokine TNF␣. We previously reported that CD146 membrane expression is also increased in response to HUVEC stimulation by LPS and IL-1, another proinflammatory cytokine. 27 Upregulation and redistribution under TNF␣ stimulation were also reported for PECAM-1, most likely attributable to a recycling of the molecule through invaginations at the lateral junction, below the membrane. 28 An apical redistribution was also described for JAM-A, 8 consistent with its involvement in leukocyte recruitment. Whereas recent data showed that MCAM/CD146 is involved in the initial steps of lymphocyte endothelium interaction, 29 in our conditions, we were unable to evidence any role of CD146 in monocyte adhesion. This discrepancy may be explained by the fact that different cell types and experimental conditions (static versus flow) were used in the 2 studies.
To our knowledge, this is the first time it is established that CD146 plays a role in monocyte transendothelial migration. Experiments were performed with THP-1 cells and confirmed with freshly isolated monocytes. Monocyte transmigration was blocked using anti-CD146 specific Ab or siRNA, whereas endothelial permeability was increased in the same conditions. Similar effects were observed using anti PECAM-1 Ab whereas anti-VE-cadherin Ab affected only endothelial monolayer permeability, as already reported. 30 This analogy between CD146 and PECAM-1 in the diapedesis process may in part be explained by their sharing many structural and functional properties. They are members of the immunoglobulin superfamily (IgSF), concentrate at the intercellular junction, and can mediate leukocyte diapedesis. These common features suggest that they may exert a redundant role. Future studies using mice carrying null mutation for CD146 and null mutations for more than 1 junctional protein will be of interest to understand whether the activities of these molecules are complementary, additive, or synergistic.
In our experiments, TNF␣ stimulation led to the generation of a soluble form of CD146, by shedding of the membrane form through a GM6001-sensitive metalloproteinase. This release was significantly larger at the apical than basal side under TNF␣ stimulation, whereas in unstimulated HUVECs no difference was observed. It is thus tempting to speculate that CD146 apical redistribution could favor this release toward the apical side, in the proximity of adherent monocytes.
Another important finding is the capacity of sCD146 to increase monocyte transmigration through endothelial cells. Although little is known about the role of soluble forms in inflammation, chimeric Fc of JAM-A 31 and PECAM-1 32 have been reported to block leukocyte transmigration by competitively inhibiting the homophilic interactions between monocytes and endothelial cells. In our study, specific binding of sCD146 was observed on both HUVECs and monocytes. Binding of sCD146 to HUVECs does not depend on endothelial CD146, consistent with a binding on a yet unknown receptor. Likewise, sCD146 binds monocytes through a heterophilic interaction because monocytes do not express CD146. It is unknown whether HUVECs and monocytes share the same receptor for sCD146.
Because the monocyte transmigration induced by sCD146 requires endothelial CD146, a potential homophilic interaction between these 2 partners was investigated. First, siRNA experiments indicated that sCD146 binding was maintained on HUVECs in the absence of CD146. Second, SPR and ELISA experiments showed no binding of sCD146 on an immobilized CD146. These data are not consistent with a homophilic interaction between cell membrane CD146 and sCD146 and are in agreement with previous data reporting heterophilic adhesion between CD146 and an unidentified ligand in melanoma cell. 33 Together our data suggest that the mechanism of action of CD146/sCD146 in transmigration involves an additional partner on monocytes that interacts with endothelial CD146. This partner could be upregulated on monocytes by sCD146.
Although the physiopathological interest of this sCD146inducible mechanism remains to be determined, the concentration of sCD146 could control the magnitude of monocyte transmigration. In this way, it has been reported that soluble CD146 concentrations decreased in the plasma of patients with inflammatory diseases such as active Crohn disease and ulcerative colitis, 17 an observation compatible with binding of sCD146 to monocytes migrating in the digestive mucosa of active patients.
Together, our results show that CD146 is regulated during an inflammatory response in vitro and designate CD146/ sCD146 as new players in monocyte transmigration. The mechanism could involve a heterophilic interaction between CD146 on endothelial cells and a not yet identified counterreceptor on monocytes. Deciphering the redundancy or the sequence by which CD146 and the other actors of the endothelial junction play their respective roles will lead to a better understanding of the mechanisms that regulate monocyte transmigration through endothelial cells.
